Onco-Innovations Announces Private Placement

Rhea-AI Summary

Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 1,428,572 units at $1.40 per unit to raise up to $2,000,000. Each unit includes one common share and one-half of a warrant, with each whole warrant exercisable at $2.00 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of shares sold and may pay finders' fees or issue finders' warrants on similar terms. Proceeds are for general corporate and R&D purposes. Closing is subject to regulatory approvals and issued securities carry a four-month-and-one-day hold. The company also appointed Christopher Gulka to the board, succeeding Graydon Bensler.

Positive

• $2.0M gross proceeds targeted from the private placement
• Each unit includes a warrant exercisable at $2.00 for 36 months
• Appointment of Christopher Gulka with 30+ years of capital markets experience

Negative

• Issuance of up to 1,428,572 shares will dilute existing shareholders
• Admin Fee Shares equal to 1.0% of placed shares add further dilution
• Private placement restricted from U.S. sales; limits investor pool
• Issued securities subject to a 4 months + 1 day hold period

Not for distribution to United States wire services or for dissemination in the United States

VANCOUVER, BC, BC / ACCESS Newswire / October 14, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 1,428,572 units of the Company (the "Units") at a price of $1.40 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit shall consist of one common share (each a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"), with each Warrant entitling the holder to purchase one Share at an exercise price of $2.00 for a period of thirty-six (36) months.

The Company also intends to issue Shares equal to 1.0% of the total of Shares issued in the Private Placement (the "Admin Fee Shares") to an arm's-length third party, as an administrative fee for their assistance with the Private Placement.

In connection with the Private Placement, the Company may pay finders' fees and/or issue finders' warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Private Placement.

Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives and for investor relations purposes.

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The Company also announces the appointment of Mr. Christopher Gulka as a member of the Board of Directors, effective immediately. Mr. Gulka brings over 30 years of experience in capital and public markets. He founded Working Capital Corporation, a corporate finance firm specializing in valuations, due diligence, and management consulting. He previously served as CFO and Director of Inner Spirit Holdings Ltd. and has held senior financial and board roles with several public companies across the mining, energy, cannabis, and industrial sectors. He holds a Bachelor of Commerce (with Distinction) from the University of Alberta and is both a Chartered Financial Analyst (CFA) and Chartered Professional Accountant (CPA). Mr. Gulka succeeds Mr. Graydon Bensler on the Board. The Company thanks Mr. Bensler for his valuable contributions and dedicated service.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

How much is Onco-Innovations (ONNVF) raising in the October 2025 private placement?

The company intends to raise up to $2,000,000 via the private placement.

What are the unit terms in Onco-Innovations' private placement (ONNVF)?

Each unit is $1.40 and includes one share plus one-half warrant; warrants exercise at $2.00 for 36 months.

How will the ONNVF private placement affect shareholder dilution?

Up to 1,428,572 shares may be issued, plus Admin Fee Shares equal to 1.0% of placed shares, increasing dilution.

When can holders of ONNVF securities from the private placement trade them?

Securities issued will be subject to a four-month-and-one-day hold period under applicable securities laws.

Who is Christopher Gulka and what is his role at Onco-Innovations (ONNVF)?

Christopher Gulka was appointed to the board effective immediately; he has over 30 years of capital and public markets experience and replaces Graydon Bensler.

Will Onco-Innovations (ONNVF) pay finders' fees for the private placement?

The company may pay finders' fees and/or issue finders' warrants on the same terms as the placement warrants to eligible parties.